July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Effects of Vitreomacular Adhesion on Treatment Outcomes in the Study of Safety and Bioactivity of TOcilizumab in Patients with Non-Infectious UVEITIS: The STOP-UVEITIS Study
Author Affiliations & Notes
  • Nam V Nguyen
    Ophthalmology, Stanford School of Medicine, Palo Alto, California, United States
    Ophthalmology, Ocular Imaging Research and Reading Center, Menlo Park, California, United States
  • Muhammad Hassan
    Ophthalmology, Stanford School of Medicine, Palo Alto, California, United States
  • Muhammad Sohail Halim
    Ophthalmology, Stanford School of Medicine, Palo Alto, California, United States
  • Rubbia Afridi
    Ophthalmology, Stanford School of Medicine, Palo Alto, California, United States
  • Sean Baluyot
    Ophthalmology, Ocular Imaging Research and Reading Center, Menlo Park, California, United States
  • Yasir Jamal Sepah
    Ophthalmology, Stanford School of Medicine, Palo Alto, California, United States
    Ophthalmology, Ocular Imaging Research and Reading Center, Menlo Park, California, United States
  • Footnotes
    Commercial Relationships   Nam Nguyen, None; Muhammad Hassan, None; Muhammad Halim, None; Rubbia Afridi, None; Sean Baluyot, None; Yasir Sepah, Genetech (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 410. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nam V Nguyen, Muhammad Hassan, Muhammad Sohail Halim, Rubbia Afridi, Sean Baluyot, Yasir Jamal Sepah; Effects of Vitreomacular Adhesion on Treatment Outcomes in the Study of Safety and Bioactivity of TOcilizumab in Patients with Non-Infectious UVEITIS: The STOP-UVEITIS Study. Invest. Ophthalmol. Vis. Sci. 2018;59(9):410.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the role of VMA in visual and anatomic outcomes in patients with non-infectious uveitis (NIU) treated with intravenous (IV) infusion of tocilizumab (TCZ)

Methods : In the STOP-Uveitis study, patients with NIU received monthly IV infusions of either 4mg/kg or 8mg/kg TCZ until month 6 (primary endpoint). Spectral domain optical coherence tomography (SD-OCT) images of patients that completed primary endpoint of the study, were analyzed at the baseline visit to identify the presence (VMA+) and absence (VMA-) of VMA. Patients with any degree of vitreomacular traction (VMT) or epiretinal membrane causing structural abnormalities within center-1mm were excluded. All images were graded by two independent graders. VMA was classified by size of adhesion into either focal (<1500 µm) or broad (≥1500 µm). Main outcome measures were mean change in visual acuity (VA), central retinal thickness (CRT), and vitreous haze (VH) at month 6. Student t-test was performed; statistical significance was set at p<0.05.

Results : A total of 37 patients were randomized in the STOP-Uveitis study. 47 eyes (27 patients) were included in the analysis. At baseline, 15 eyes were classified as VMA (+), and 32 eyes were classified as VMA(-). The baseline characteristics are shown in Table 1. At month 6, the VMA(+) showed a mean improvement of 2.07±3.63 letters, whereas the VMA (-) group showed a mean improvement of 6.94 ± 9.49 letters. The difference between the two groups was considered statistically significant (p=0.016). The mean improvement in CRT was 23.9±54.2 µm and 80.4±157.2 µm in the VMA(+) and VMA(-) groups, respectively (p=0.081). The mean change in VH was -0.63±0.38 and -0.76±0.71 in VMA(+) and VMA(-) groups, respectively (p=0.420). Out of 15 eyes, 2 eyes showed complete resolution of VMA at month 6, and one eye the VMA grade was reduced from broad to focal.

Conclusions : The presence of VMA seems to contribute to suboptimal improvement in vision in subjects receiving treatment for uveitis, even though the changes in CRT and VH did not differ due the presence of VMA.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×